JP2023523319A5 - - Google Patents

Info

Publication number
JP2023523319A5
JP2023523319A5 JP2022565563A JP2022565563A JP2023523319A5 JP 2023523319 A5 JP2023523319 A5 JP 2023523319A5 JP 2022565563 A JP2022565563 A JP 2022565563A JP 2022565563 A JP2022565563 A JP 2022565563A JP 2023523319 A5 JP2023523319 A5 JP 2023523319A5
Authority
JP
Japan
Prior art keywords
seq
identity
polynucleotide sequence
composition according
bacteriophage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022565563A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023523319A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/029412 external-priority patent/WO2021222257A1/en
Publication of JP2023523319A publication Critical patent/JP2023523319A/ja
Publication of JP2023523319A5 publication Critical patent/JP2023523319A5/ja
Pending legal-status Critical Current

Links

JP2022565563A 2020-04-27 2021-04-27 シュードモナス感染症を処置するためのバクテリオファージ組成物 Pending JP2023523319A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063016132P 2020-04-27 2020-04-27
US63/016,132 2020-04-27
PCT/US2021/029412 WO2021222257A1 (en) 2020-04-27 2021-04-27 Bacteriophage compositions for treating pseudomonas infection

Publications (2)

Publication Number Publication Date
JP2023523319A JP2023523319A (ja) 2023-06-02
JP2023523319A5 true JP2023523319A5 (enExample) 2024-05-13

Family

ID=76284135

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022565563A Pending JP2023523319A (ja) 2020-04-27 2021-04-27 シュードモナス感染症を処置するためのバクテリオファージ組成物

Country Status (8)

Country Link
US (3) US12594312B2 (enExample)
EP (1) EP4142760A1 (enExample)
JP (1) JP2023523319A (enExample)
CN (1) CN116018154A (enExample)
AU (1) AU2021263735A1 (enExample)
CA (1) CA3179361A1 (enExample)
IL (1) IL296741A (enExample)
WO (1) WO2021222257A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1879573T3 (pl) 2005-05-10 2013-05-31 Incyte Holdings Corp Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania
US12594312B2 (en) * 2020-04-27 2026-04-07 Armata Pharmaceuticals, Inc. Bacteriophage compositions for treating Pseudomonas infection
WO2025143108A1 (ja) * 2023-12-27 2025-07-03 株式会社Arrowsmith 緑膿菌バクテリオファージ
WO2025219447A1 (en) 2024-04-17 2025-10-23 Hun-Ren Biological Research Centre Szeged Region-specific phage compositions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2833899T3 (da) * 2012-03-19 2020-09-28 Tecnifar Ind Tecnica Farmaceutica S A Sammensætninger, der omfatter cocktails af antibakterielle fager, og anvendelser deraf til behandling af bakterieinfektioner
EP2865383A1 (en) 2013-10-25 2015-04-29 Pherecydes Pharma Phage therapy of pseudomonas infections
EP3018201A1 (en) * 2014-11-07 2016-05-11 Pherecydes Pharma Phage therapy
US11672839B2 (en) * 2016-12-05 2023-06-13 Technechnophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa Bacteriophage compositions comprising respiratory antibacterial phages and methods of use thereof
WO2018151416A1 (ko) * 2017-02-17 2018-08-23 주식회사 인트론바이오테크놀로지 신규한 녹농균 박테리오파지 Pse-AEP-3 및 이의 녹농균 증식 억제 용도
WO2019136108A1 (en) * 2018-01-02 2019-07-11 Ampliphi Biosciences Corporation Bacteriophage compositions for treating pseudomonas infections
US12594312B2 (en) 2020-04-27 2026-04-07 Armata Pharmaceuticals, Inc. Bacteriophage compositions for treating Pseudomonas infection

Similar Documents

Publication Publication Date Title
JP2023523319A5 (enExample)
Łusiak-Szelachowska et al. Bacteriophages and antibiotic interactions in clinical practice: what we have learned so far
JP7154543B2 (ja) 呼吸器抗菌性ファージを含むバクテリオファージ組成物、およびその使用法
US12239677B2 (en) Therapeutic bacteriophage compositions for treating Staphylococcus infection
Zhang et al. Bacteriophage effectively kills multidrug resistant Staphylococcus aureus clinical isolates from chronic rhinosinusitis patients
JP7812496B2 (ja) 呼吸器抗菌性ファージを含むカクテル組成物及びその使用方法
Kelly et al. Development of a broad-host-range phage cocktail for biocontrol
IL277119B2 (en) Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof
US12594312B2 (en) Bacteriophage compositions for treating Pseudomonas infection
Naseef Pathoor et al. Understanding the biofilm development of Acinetobacter baumannii and novel strategies to combat infection
Ming et al. The antibacterial effects of antimicrobial peptides OP-145 against clinically isolated multi-resistant strains
US20210361727A1 (en) Bacteriophage compositions for treating pseudomonas infections
Nicholls et al. Role of bacteriophage therapy for resistant infections in transplant recipients
Łusiak-Szelachowska et al. Anti-biofilm activity of bacteriophages and lysins in chronic rhinosinusitis.
Selim et al. Phage therapeutic delivery methods and clinical trials for combating clinically relevant pathogens
JP2024530170A5 (enExample)
Wang et al. Bacteriophages and their derived enzymes as promising alternatives for the treatment of Acinetobacter baumannii infections: M. Wang et al.
JP2023513934A5 (enExample)
Babita et al. Phage Therapy Reimagined: Viral Solutions for Antibiotic Resistant Challenges
Nachimuthu et al. Reviving Phage Therapy: A Novel Approach to Treat Respiratory-Associated Infections
Yamano et al. 723. Synergistic Effect of Cefiderocol Combined With Other Antibiotics Against Cefiderocol High MIC Isolates From the Multi-National SIDERO-WT Studies
CA3045284C (en) Bacteriophage compositions comprising respiratory antibacterial phages and methods of use thereof
HK40040296A (en) Therapeutics bacteriophage compositions for treating staphylococcus infection
Rana et al. Multidrug-resistant organisms in Solid Organ Transplantation
JP2023513934A (ja) ブドウ球菌感染症を処置するためのバクテリオファージ組成物